Aminoguanidine inhibits advanced glycation end products formation on β2-microglobulin

Journal of the American Society of Nephrology

Volumn 9, Issue 2, 1998, Pages 277-283

  Hou, Fan Fan ^a,b   Boyce, Joshua ^a   Chertow, Glenn M ^a   Kay, Jonathan ^c   Owen, William F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b FIRST MILITARY MEDICAL UNIVERSITY   (China)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; ANTIBODY; BETA 2 MICROGLOBULIN; COLLAGEN TYPE 1; GLUCOSE; HYDRAZINE DERIVATIVE; KEYHOLE LIMPET HEMOCYANIN; LYSINE DERIVATIVE;

AMYLOIDOSIS; ARTICLE; CONTROLLED STUDY; DIALYSIS; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROMETRY; IMMUNOBLOTTING; PRIORITY JOURNAL;

EID: 0031913603     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Kay J: Beta 2-microglobulin amyloidosis: Amyloid. Int J Exp Clin Invest 1997, in press
2. Drueke T, Touam M, Zingraff J: Dialysis-associated amyloidosis. Adv Ren Replace Ther 2: 24-39, 1995
3. Zingraff J, Drueke T: Can the nephrologist prevent dialysis-related amyloidosis? Am J Kidney Dis 18: 1-11, 1991
4. Hakim RM, Wingard RL, Husni L, Parker RA, Parker TF III: The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients. J Am Soc Nephrol 7: 472-478, 1996
5. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, Horiuchi S, Taniguchi N, Maeda K, Kinoshita T: β2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 29: 1243-1252, 1993
6. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O, Maeda K, Seo H: Involvement of β2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 93: 521-528, 1994
7. Iida Y, Miyata T, Inagi R, Sugiyama S, Maeda K: Beta 2-microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: Role in the pathogenesis of hemodialysis-associated amyloidosis. Biochem Biophys Res Commun 201: 1235-1241, 1994
8. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321, 1988
9. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629-1632, 1986
10. Bucala R, Vlassara H: Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 26: 875-888, 1995
11. Vlassara H, Brownlee M, Cerami A: High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 82: 5588-5592, 1985
12. Hou FF, Chertow GM, Kay J, Boyce J, Lazarus JM, Braatz JA, Owen WF Jr: The interaction between β2-microglobulin and advanced glycation end products in the development of dialysis-related amyloidosis. Kidney Int 51: 1514-1519, 1997
13. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976
14. ∈-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878, 1995
15. Araki N, Ueno N, Chakrabarti B, Morino Y, Horiuchi S: Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J Biol Chem 267: 10211-10214, 1992
16. Miyata T, Iida Y, Ueda Y, Shinzato T, Seo H, Monnier VM, Maeda K, Wada Y: Monocyte/macrophage response to β2-microglobulin modified with advance glycation end products. Kidney Int 49: 538-550, 1996
17. Horiuchi S, Araki N, Morino Y: Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. J Biol Chem 266: 7329-7332, 1991
18. Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267: 5133-5138, 1992
19. Njoroge FG, Monnier VM: The chemistry of the Maillard reaction under physiological conditions: A review. Prog Clin Biol Res 304: 85-107, 1989
20. Ledl F, Schliecher E: New aspects of the Maillard reaction in foods and in the human body. Angew Chem Int Ed Engl 29: 565-706, 1990
21. Bucala R, Cerami A: Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 23: 1-34, 1992
22. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW: Glycation, glycoxidation, and cross-linking of collagen by glucose. Diabetes 43: 676-683, 1994
23. Ellis EN, Good BH: Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 40: 1016-1019, 1991
24. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88: 11555-11558, 1991
25. Huijberts MSP, Wolffenbuttel BHR, Struijker-Boudier HAJ, Crijns FRL: Aminoguanidine treatment increases elasticity and decreases fluid retention of large arteries from diabetic rats. J Clin Invest 92: 1407-1411, 1993
26. Cameron NE, Cotter MA, Dines K, Love A: Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 35: 946-950, 1992
27. ∈-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney Int 50: 1303-1309, 1996
28. Ahmed MU, Thorpe SR, Baynes JW: Identification of carboxymethyl lysine as a degradation product of fructosyllysine in glycated protein. J Biol Chem 261: 4889-4894, 1986
29. ∈-(carboxymethyl)lysine in lens proteins. Biochemistry 28: 9464-9468, 1989
30. ∈-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 30: 1205-1210, 1991
31. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, Baynes JW: Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91: 2463-2469, 1993
32. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, Lyons TJ: Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91: 2470-2478, 1993
33. Assounga AG, Bascoul S, Canaud B, Bouya PA, Vendrell JP, Sciolla JP, Mourad G, Baldet P, Serre A, Mion C: A study of β2-microglobulin skin deposits in dialyzed patients and healthy controls. Am J Kidney Dis 15: 555-561, 1990
34. Jadoul M, Malghem J, Pirson Y: Effect of renal transplantation on the radiological signs of dialysis amyloid arthropathy. Clin Nephrol 32: 194-197, 1989
35. Sethi D, Brown EA, Gower PE: Renal transplantation for dialysis arthropathy. Lancet 2: 448-449, 1988
36. Bardin T, Lebail-Darne JL, Zingraff J, Laredo JD, Voisin MC, Kreis H, Kuntz D: Dialysis arthropathy: Outcome after renal transplantation. Am J Med 99: 243-248, 1995